Journal of Japan Society of Pain Clinicians
Online ISSN : 1884-1791
Print ISSN : 1340-4903
ISSN-L : 1340-4903
Successful restarting of low-dose pregabalin: a report of 4 cases
Tomoyuki SAITOYuichi HASHIMOTOShunsuke SAIMAEriko ADACHIKeiko OKUDAMutsuhisa SHIMAZAKIMayumi TACHIKAWATakero ARAIYasuhisa OKUDA
Author information
JOURNAL FREE ACCESS

2012 Volume 19 Issue 4 Pages 516-518

Details
Abstract
Although pregabalin is a first-line drug for neuropathic pain, including postherpetic neuralgia (PHN), it may cause some side effects, such as dizziness, somnolence, dose-dependent peripheral edema, and weight gain, which may influence patients to abandon its use. When pregabalin is used for PHN, the starting dose is usually 150 mg taken twice a day. We report four cases that at another hospital had discontinued pregabalin at 150 mg/day because of adverse effects. It was re-started in our department at 75 mg/day, which was gradually increased to 150 mg/day. All patients were able to continue pregabalin without adverse effects, which led to substantial improvement in the symptoms of two patients. For elderly patients, it may be appropriate to start at a low dose, wait until the side effects go away, and then gradually increase the dose until the benefits take effect.
Content from these authors
© 2012 Japan Society of Pain Clinicians
Previous article Next article
feedback
Top